IP Library Granted Patent US 8,673,944
Granted Patent B2
US 8,673,944 · App. 13/139,426 · Granted Mar 18, 2014

Solid pharmaceutical composition comprising amlodipine and losartan with improved stability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,944
App. No.
13/139,426
Granted
Mar 18, 2014
Kind
B2
Abstract

The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.

Claims (11)

1. A solid pharmaceutical composition comprising granular forms of amlodipine and losartan which are separated from each other, and a stabilizing agent,

wherein the stabilizing agent is an antioxidant selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole, tocopherol, ascorbic acid, erythorbic acid, citric acid, ascorbyl palmitic acid, ethylene diamine tetracetic acid, sodium pyrosulfite, and a mixture thereof; and

wherein the stabilizing agent is used in an amount ranging from 0.005 to 5% by weight based on the total weight of the composition.

2. The composition of claim 1 , wherein the anti-oxidant is a neutral anti-oxidant.

3. The composition of claim 2 , wherein the neutral anti-oxidant is butylated hydroxytoluene, butylated hydroxyanisole, or tocopherol.

4. The composition of claim 1 , wherein the stabilizing agent is confined within the amlodipine granules.

5. The composition of claim 1 , wherein the stabilizing agent is used in an amount ranging from 0.01 to 1% by weight based on the total weight of the composition.

6. The composition of claim 5 , wherein the stabilizing agent is used in an amount ranging from 0.02 to 0.5% by weight based on the total weight of the composition.

7. The composition of claim 1 , wherein amlodipine and losartan are used in a weight ratio of the range of 1:1 to 1:40.

8. A method of treating a cardiovascular disorder comprising administering the composition of claim 1 in an effective amount into a subject in need thereof.

9. The method of claim 8 , wherein the cardiovascular disorder is selected from the group consisting of angina pectoris, hypertension, artery vasospasm, deep vein, cardiac hypertrophy, cerebral infarct, congestive heart failure, and myocardial infarction.

Assignments (2)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2011
From: PARK, JAE HYUN; KIM, KYEONG SOO; YIM, HO TAEK; IM, JI HYUN
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 026438/0278 →